CollPlant Biotechnologies Ltd. (CLGN)
4.19
+0.08
(+1.95%)
USD |
NASDAQ |
Nov 04, 15:40
CollPlant Biotechnologies Enterprise Value : 5.646M for Nov. 3, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 03, 2026 | 5.646M |
| November 02, 2026 | 5.602M |
| October 30, 2026 | 5.682M |
| October 29, 2026 | 6.064M |
| October 28, 2026 | 5.414M |
| October 27, 2026 | 5.342M |
| October 26, 2026 | 5.126M |
| October 23, 2026 | 5.010M |
| October 22, 2026 | 4.938M |
| October 21, 2026 | 5.133M |
| October 20, 2026 | 5.313M |
| October 19, 2026 | 4.851M |
| October 16, 2026 | 4.945M |
| October 15, 2026 | 5.024M |
| October 14, 2026 | 5.674M |
| October 13, 2026 | 5.357M |
| October 12, 2026 | 5.516M |
| October 09, 2026 | 4.779M |
| October 08, 2026 | 5.443M |
| October 07, 2026 | 4.707M |
| October 06, 2026 | 4.606M |
| October 05, 2026 | 4.634M |
| October 02, 2026 | 4.707M |
| October 01, 2026 | 4.866M |
| September 30, 2026 | 5.169M |
| Date | Value |
|---|---|
| September 29, 2026 | 5.183M |
| September 28, 2026 | 5.299M |
| September 25, 2026 | 5.848M |
| September 24, 2026 | 5.660M |
| September 23, 2026 | 5.544M |
| September 22, 2026 | 5.270M |
| September 21, 2026 | 5.920M |
| September 18, 2026 | 6.296M |
| September 17, 2026 | 5.718M |
| September 16, 2026 | 4.736M |
| September 15, 2026 | 4.62M |
| September 14, 2026 | 4.75M |
| September 11, 2026 | 4.764M |
| September 10, 2026 | 4.822M |
| September 09, 2026 | 4.634M |
| September 08, 2026 | 4.88M |
| September 04, 2026 | 4.837M |
| September 03, 2026 | 4.637M |
| September 02, 2026 | 4.668M |
| September 01, 2026 | 5.091M |
| August 31, 2026 | 5.312M |
| August 28, 2026 | 4.88M |
| August 27, 2026 | 3.893M |
| August 26, 2026 | 4.150M |
| August 25, 2026 | 3.898M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 247.14M |
| Perspective Therapeutics, Inc. | -132.52M |
| MiMedx Group, Inc. | 353.47M |
| Regentis Biomaterials Ltd. | 51.99M |
| Xylo Technologies Ltd. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.726M |
| Revenue (Quarterly) | 0.108M |
| Total Expenses (Quarterly) | 2.834M |
| EPS Diluted (Quarterly) | -1.890 |
| Gross Profit Margin (Quarterly) | -604.6% |
| Profit Margin (Quarterly) | -2.52K% |
| Earnings Yield | -62.99% |
| Normalized Earnings Yield | -62.99 |